854934-71-7

Basic information

• Product Name: (3S)-1-azabicyclo[2.2.2]oct-3-yl benzoate (D)-tartrate
• Synonyms: (3S)-1-azabicyclo[2.2.2]oct-3-yl benzoate (D)-tartrate
• CAS NO: 854934-71-7
• Molecular Weight: 381.383
• Mol File: 854934-71-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (3S)-1-azabicyclo[2.2.2]oct-3-yl benzoate (D)-tartrate(CAS DataBase Reference)
• NIST Chemistry Reference: (3S)-1-azabicyclo[2.2.2]oct-3-yl benzoate (D)-tartrate(854934-71-7)
• EPA Substance Registry System: (3S)-1-azabicyclo[2.2.2]oct-3-yl benzoate (D)-tartrate(854934-71-7)

Safety Data

• Hazardous Substances Data: 854934-71-7(Hazardous Substances Data)

Upstream product

• 66-93-3 3-quinuclidinol benzoate 
• 147-71-7 D-tartaric acid 
• 87-69-4 L-Tartaric acid 

Relevant articles and documents

FUSED BICYCLOHETEROCYCLE SUBSTITUTED QUINUCLIDINE DERIVATIVES

Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+-O-; X is O, S, -NH-, and -N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by a7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.

3-quinuclidinyl amino-substituted biaryl derivatives

Compounds of formula (I) wherein n is 0, 1, or 2; Y is O, S, —NH—, and —N-alkyl-; Ar1 is both 6-membered aromatic rings; Ar2 is 5- or 6-membered aromatic rings with a —NR8R9 group, as defined herein. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.

3-Quinuclidinyl amino-substituted biaryl derivatives

Compounds of formula (I) wherein A is N or N+—O?; n is 0, 1, or 2; Y is O, S, —NH—, and —N-alkyl-; Ar1 is both 6-membered aromatic rings; Ar2 is 5- or 6-membered aromatic rings with a —NR8R9 group, as defined herein. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.